HSL-AD Molecular Pathology
HSL-AD offers the Zytovision VisionArray HPV Genotyping Assay, the Prosigna Breast Cancer Assay and, in partnership, a next-generation sequencing service for routine cancer diagnostics and oncology clinical trials.
HSL-AD participates in external quality assurance (EQA) across various modules through UK NEQAS ICC & ISH, NordiQC, and GenQA. For tests not covered by conventional EQA schemes within the previous 12 months, an alternative approach to EQA is implemented to ensure ongoing quality assessment.
Molecular tests
Test name |
---|
EGFR mutation |
Zytovision VisionArray HPV Genotyping Assay |
Prosigna Breast Cancer Assay |
Next-generation sequencing (NGS) service
HSL-AD partners with Sarah Cannon Molecular Diagnostics to provide a next-generation sequencing service for routine cancer diagnostics and oncology clinical trials.
Tests available include:
- MGP-4: An NGS-based test, looking at tumour derived DNA and/or RNA, to help guide targeted therapy use
- MGP-5: An NGS-based test, looking at tumour derived DNA, to help guide PARP inhibitor use
- Rapid-turnaround tests, looking at selected biomarkers only to help guide key personalised therapy options
- MSI and MLH-1 promoter methylation analysis
- Endopredict test (Myriad Genetics)
Contact details:
Sarah Cannon Molecular Diagnostics
Ground Floor, Shropshire House,
1 Capper Street
London, WC1E 6JA.
Tel: 020 3794 1920
Email: info@sarahcannon-md.co.uk
www.sarahcannon-md.co.uk